The qPCR analysis of the six key targets (AKT1, HSP90AA1, CASP3, MAPK3, VEGFA, and MMP7) previously identified in the network pharmacology study provided insights into the potential molecular mechanisms underlying the therapeutic effects of AM and RPR on IPF. This evidence concerns the gene HSP90AA1 and idiopathic pulmonary fibrosis.